Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus

Michael R. Pranzatelli, Elizabeth D. Tate, Shalini Shenoy, Anna L. Travelstead

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Ofatumumab is a fully human anti-CD20 monoclonal antibody in phase II-III trials for various autoimmune and lymphoreticular diseases. We used it to treat a rituximab-allergic child with severe, chronic-relapsing, opsoclonus-myoclonus syndrome (OMS), characterized by persistent cerebrospinal fluid (CSF) B-cell expansion and T-cell dysregulation. He had relapsed despite chemotherapy, plasma exchange with immunoadsorption, and resection of ganglioneuroblastoma, detected 3 years after OMS onset. The four ofatumumab infusions (1,195mg/m 2 total dose) were well tolerated, and CSF B-cell expansion was eliminated. No further relapses have occurred in 3 years, but he remains on low-dose ACTH with neuropsychiatric residuals of OMS.

Original languageEnglish
Pages (from-to)988-991
Number of pages4
JournalPediatric Blood and Cancer
Issue number6
StatePublished - Jun 1 2012


  • Anti-B-cell therapy
  • Ganglioneuroblastoma
  • Paraneoplastic disorder
  • Plasma exchange/immunoadsorption


Dive into the research topics of 'Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus'. Together they form a unique fingerprint.

Cite this